Loading...
Loading...
Analysts at UBS downgraded
Impax Laboratories IncIPXL from Neutral to Sell.
Impax Laboratories shares have gained 99.84 percent over the past 52 weeks, while the S&P 500 index has gained 12.45 percent in the same period.
Impax Laboratories' shares declined 3.04 percent to $49.70 in pre-market trading.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in